Details of the Drug

General Information of Drug (ID: DMO946V)

Drug Name
Ticlopidine
Synonyms
Ticlid; Ticlopidina; Ticlopidinum; PCR 5332; Ticlid (TN); Ticlopidin-Puren; Ticlopidina [INN-Spanish]; Ticlopidine (INN); Ticlopidine [INN:BAN]; Ticlopidinum [INN-Latin]; Ticlopidin-Puren (TN); 5-((2-Chlorophenyl)methyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine; 5-(2-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; 5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine
Indication
Disease Entry ICD 11 Status REF
Stroke 8B20 Approved [1], [2]
Therapeutic Class
Fibrinolytic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 263.8
Topological Polar Surface Area (xlogp) 3.6
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption
The absorption of drug is greater than 80% [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
80% of drug becomes completely available to its intended biological destination(s) [5]
Elimination
0.5% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 7.9 hours (in subjects 20 - 43 years of age with 250 mg dose) [6]
Metabolism
The drug is metabolized via the liver [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 15.80795 micromolar/kg/day [7]
Chemical Identifiers
Formula
C14H14ClNS
IUPAC Name
5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine
Canonical SMILES
C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl
InChI
InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2
InChIKey
PHWBOXQYWZNQIN-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5472
ChEBI ID
CHEBI:9588
CAS Number
55142-85-3
DrugBank ID
DB00208
TTD ID
D05LBU
VARIDT ID
DR00842
INTEDE ID
DR1592
ACDINA ID
D00675

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Platelet-activating factor receptor (PTAFR) TTQL5VC PTAFR_HUMAN Modulator [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [9]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [10]
Myeloperoxidase (MPO) DEA3U9Y PERM_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Stroke
ICD Disease Classification 8B20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Platelet-activating factor receptor (PTAFR) DTT PTAFR 3.53E-02 0.33 2.12
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 6.05E-02 2.38E-01 2.17E+00
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 8.44E-02 -5.80E-01 -1.74E+00
Myeloperoxidase (MPO) DME MPO 3.56E-01 1.54E-01 1.04E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ticlopidine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Minor Decreased absorption of Ticlopidine due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [44]
Donepezil DMIYG7Z Minor Decreased metabolism of Ticlopidine caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [45]
Ranolazine DM0C9IL Minor Decreased metabolism of Ticlopidine caused by Ranolazine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [46]
Clobazam - Lundbeck DMW1OQ0 Moderate Decreased metabolism of Ticlopidine caused by Clobazam - Lundbeck mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [47]
Cilostazol DMZMSCT Major Decreased metabolism of Ticlopidine caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [48]
Roflumilast DMPGHY8 Moderate Decreased metabolism of Ticlopidine caused by Roflumilast mediated inhibition of CYP450 enzyme. Asthma [CA23] [48]
Atomoxetine DM5L6HI Moderate Decreased metabolism of Ticlopidine caused by Atomoxetine mediated inhibition of CYP450 enzyme. Attention deficit hyperactivity disorder [6A05] [49]
Pentosan polysulfate DM2HRKE Moderate Increased risk of bleeding by the combination of Ticlopidine and Pentosan polysulfate. Chronic pain [MG30] [50]
Phenylbutazone DMAYL0T Moderate Increased risk of bleeding by the combination of Ticlopidine and Phenylbutazone. Chronic pain [MG30] [44]
Ketoprofen DMRKXPT Moderate Increased risk of bleeding by the combination of Ticlopidine and Ketoprofen. Chronic pain [MG30] [44]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Ticlopidine and Levomilnacipran. Chronic pain [MG30] [51]
Anisindione DM2C48U Moderate Increased risk of bleeding by the combination of Ticlopidine and Anisindione. Coagulation defect [3B10] [52]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Ticlopidine and Regorafenib. Colorectal cancer [2B91] [48]
Intedanib DMSTA36 Moderate Increased risk of bleeding by the combination of Ticlopidine and Intedanib. Colorectal cancer [2B91] [53]
Levobupivacaine DM783CH Moderate Decreased metabolism of Ticlopidine caused by Levobupivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [48]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Ticlopidine and Ardeparin. Coronary thrombosis [BA43] [54]
Dextromethorphan DMUDJZM Moderate Decreased metabolism of Ticlopidine caused by Dextromethorphan mediated inhibition of CYP450 enzyme. Cough [MD12] [55]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Ticlopidine and Danaparoid. Deep vein thrombosis [BD71] [54]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Ticlopidine and Rivaroxaban. Deep vein thrombosis [BD71] [56]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Ticlopidine and Sertraline. Depression [6A70-6A7Z] [51]
Fluoxetine DM3PD2C Moderate Increased risk of bleeding by the combination of Ticlopidine and Fluoxetine. Depression [6A70-6A7Z] [51]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Ticlopidine and Vilazodone. Depression [6A70-6A7Z] [51]
Paroxetine DM5PVQE Moderate Increased risk of bleeding by the combination of Ticlopidine and Paroxetine. Depression [6A70-6A7Z] [51]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Ticlopidine and Vortioxetine. Depression [6A70-6A7Z] [51]
Duloxetine DM9BI7M Moderate Increased risk of bleeding by the combination of Ticlopidine and Duloxetine. Depression [6A70-6A7Z] [51]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Ticlopidine and Milnacipran. Depression [6A70-6A7Z] [51]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Ticlopidine and Escitalopram. Depression [6A70-6A7Z] [57]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Ticlopidine and Desvenlafaxine. Depression [6A70-6A7Z] [51]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Ticlopidine and Clomipramine. Depression [6A70-6A7Z] [51]
Venlafaxine DMR6QH0 Moderate Increased risk of bleeding by the combination of Ticlopidine and Venlafaxine. Depression [6A70-6A7Z] [51]
Heme DMGC287 Moderate Increased risk of bleeding by the combination of Ticlopidine and Heme. Discovery agent [N.A.] [58]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Ticlopidine and Apigenin. Discovery agent [N.A.] [59]
Citalopram derivative 1 DMITX1G Major Decreased metabolism of Ticlopidine caused by Citalopram derivative 1 mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [60]
PMID28870136-Compound-49 DMTUC9E Moderate Increased risk of bleeding by the combination of Ticlopidine and PMID28870136-Compound-49. Discovery agent [N.A.] [61]
Fenfluramine DM0762O Moderate Increased risk of bleeding by the combination of Ticlopidine and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [51]
Stiripentol DMMSDOY Moderate Decreased metabolism of Ticlopidine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [48]
Phenytoin DMNOKBV Moderate Decreased metabolism of Ticlopidine caused by Phenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [62]
Fosphenytoin DMOX3LB Moderate Decreased metabolism of Ticlopidine caused by Fosphenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [62]
Brivaracetam DMSEPK8 Minor Decreased metabolism of Ticlopidine caused by Brivaracetam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [48]
Ethotoin DMXWOCP Moderate Decreased metabolism of Ticlopidine caused by Ethotoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [63]
Phenobarbital DMXZOCG Minor Decreased metabolism of Ticlopidine caused by Phenobarbital mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [64]
Cannabidiol DM0659E Minor Decreased metabolism of Ticlopidine caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [48]
Timolol DM3NXRU Moderate Decreased metabolism of Ticlopidine caused by Timolol mediated inhibition of CYP450 enzyme. Essential hypertension [BA00] [65]
Suprofen DMKXJZ7 Moderate Increased risk of bleeding by the combination of Ticlopidine and Suprofen. Eye anterior segment structural developmental anomaly [LA11] [66]
Mefenamic acid DMK7HFI Moderate Increased risk of bleeding by the combination of Ticlopidine and Mefenamic acid. Female pelvic pain [GA34] [44]
Tolterodine DMSHPW8 Minor Decreased metabolism of Ticlopidine caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [67]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Ticlopidine caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [68]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Ticlopidine and Avapritinib. Gastrointestinal stromal tumour [2B5B] [48]
Tipranavir DM8HJX6 Major Increased risk of bleeding by the combination of Ticlopidine and Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [69]
Etravirine DMGV8QU Moderate Decreased metabolism of Ticlopidine caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [70]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Ticlopidine caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [48]
Meclofenamic acid DM05FXR Moderate Increased risk of bleeding by the combination of Ticlopidine and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [44]
Ramelteon DM7IW9J Moderate Decreased metabolism of Ticlopidine caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [71]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Ticlopidine caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [72]
Alosetron DML2A03 Moderate Decreased metabolism of Ticlopidine caused by Alosetron mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [73]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Ticlopidine caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [74]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Ticlopidine and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [75]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Ticlopidine and Acalabrutinib. Mature B-cell lymphoma [2A85] [76]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Ticlopidine and Ibrutinib. Mature B-cell lymphoma [2A85] [77]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Ticlopidine and Ponatinib. Mature B-cell lymphoma [2A85] [78]
Nitisinone DMVS9WQ Moderate Decreased metabolism of Ticlopidine caused by Nitisinone mediated inhibition of CYP450 enzyme. Metabolism inborn error [5C50] [61]
Flibanserin DM70DTN Moderate Decreased metabolism of Ticlopidine caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [79]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Ticlopidine and Panobinostat. Multiple myeloma [2A83] [55]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Ticlopidine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [48]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Ticlopidine and Dasatinib. Myeloproliferative neoplasm [2A20] [80]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Ticlopidine and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [50]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Ticlopidine and Prasugrel. Myocardial infarction [BA41-BA43] [48]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Ticlopidine and Vorapaxar. Myocardial infarction [BA41-BA43] [81]
Tirofiban DMQG17S Major Increased risk of bleeding by the combination of Ticlopidine and Tirofiban. Myocardial infarction [BA41-BA43] [82]
Bupropion DM5PCS7 Moderate Decreased metabolism of Ticlopidine caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [55]
Sibutramine DMFJTDI Moderate Increased risk of bleeding by the combination of Ticlopidine and Sibutramine. Obesity [5B80-5B81] [83]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Ticlopidine and Dexfenfluramine. Obesity [5B80-5B81] [83]
Diclofenac DMPIHLS Moderate Increased risk of bleeding by the combination of Ticlopidine and Diclofenac. Osteoarthritis [FA00-FA05] [44]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Ticlopidine and Nepafenac. Osteoarthritis [FA00-FA05] [66]
Naproxen DMZ5RGV Moderate Increased risk of bleeding by the combination of Ticlopidine and Naproxen. Osteoarthritis [FA00-FA05] [44]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Ticlopidine and MK-4827. Ovarian cancer [2C73] [48]
Aspirin DM672AH Moderate Increased risk of bleeding by the combination of Ticlopidine and Aspirin. Pain [MG30-MG3Z] [44]
Etodolac DM6WJO9 Moderate Increased risk of bleeding by the combination of Ticlopidine and Etodolac. Pain [MG30-MG3Z] [44]
Diflunisal DM7EN8I Moderate Increased risk of bleeding by the combination of Ticlopidine and Diflunisal. Pain [MG30-MG3Z] [44]
Ibuprofen DM8VCBE Moderate Increased risk of bleeding by the combination of Ticlopidine and Ibuprofen. Pain [MG30-MG3Z] [44]
Nabumetone DMAT2XH Moderate Increased risk of bleeding by the combination of Ticlopidine and Nabumetone. Pain [MG30-MG3Z] [44]
Codeine DMJX6ZG Moderate Decreased metabolism of Ticlopidine caused by Codeine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [84]
Rasagiline DM3WKQ4 Major Decreased metabolism of Ticlopidine caused by Rasagiline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [55]
Ropinirole DMA6S1D Moderate Decreased metabolism of Ticlopidine caused by Ropinirole mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [85]
Ketorolac DMI4EL5 Moderate Increased risk of bleeding by the combination of Ticlopidine and Ketorolac. Postoperative inflammation [1A00-CA43] [44]
Bromfenac DMKB79O Moderate Increased risk of bleeding by the combination of Ticlopidine and Bromfenac. Postoperative inflammation [1A00-CA43] [44]
Treprostinil DMTIQF3 Moderate Increased risk of bleeding by the combination of Ticlopidine and Treprostinil. Pulmonary hypertension [BB01] [86]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Ticlopidine and Epoprostenol. Pulmonary hypertension [BB01] [86]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Ticlopidine and Iloprost. Pulmonary hypertension [BB01] [86]
Meloxicam DM2AR7L Moderate Increased risk of bleeding by the combination of Ticlopidine and Meloxicam. Rheumatoid arthritis [FA20] [44]
Sulindac DM2QHZU Moderate Increased risk of bleeding by the combination of Ticlopidine and Sulindac. Rheumatoid arthritis [FA20] [44]
Oxaprozin DM9UB0P Moderate Increased risk of bleeding by the combination of Ticlopidine and Oxaprozin. Rheumatoid arthritis [FA20] [44]
Flurbiprofen DMGN4BY Moderate Increased risk of bleeding by the combination of Ticlopidine and Flurbiprofen. Rheumatoid arthritis [FA20] [44]
Fenoprofen DML5VQ0 Moderate Increased risk of bleeding by the combination of Ticlopidine and Fenoprofen. Rheumatoid arthritis [FA20] [44]
Indomethacin DMSC4A7 Moderate Increased risk of bleeding by the combination of Ticlopidine and Indomethacin. Rheumatoid arthritis [FA20] [44]
Tolmetin DMWUIJE Moderate Increased risk of bleeding by the combination of Ticlopidine and Tolmetin. Rheumatoid arthritis [FA20] [44]
Thioridazine DM35M8J Major Decreased metabolism of Ticlopidine caused by Thioridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [87]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Ticlopidine caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [88]
Asenapine DMSQZE2 Moderate Decreased metabolism of Ticlopidine caused by Asenapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [89]
Pimozide DMW83TP Moderate Decreased metabolism of Ticlopidine caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [90]
Curcumin DMQPH29 Minor Increased risk of bleeding by the combination of Ticlopidine and Curcumin. Solid tumour/cancer [2A00-2F9Z] [91]
Pitolisant DM8RFNJ Moderate Decreased metabolism of Ticlopidine caused by Pitolisant mediated inhibition of CYP450 enzyme. Somnolence [MG42] [48]
Warfarin DMJYCVW Moderate Increased risk of bleeding by the combination of Ticlopidine and Warfarin. Supraventricular tachyarrhythmia [BC81] [52]
Caplacizumab DMPUKA7 Major Increased risk of bleeding by the combination of Ticlopidine and Caplacizumab. Thrombocytopenia [3B64] [55]
Anagrelide DMSQ8MD Moderate Decreased metabolism of Ticlopidine caused by Anagrelide mediated inhibition of CYP450 enzyme. Thrombocytosis [3B63] [92]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Ticlopidine and Apixaban. Thrombosis [DB61-GB90] [48]
Cangrelor DM8JRH0 Major Increased risk of bleeding by the combination of Ticlopidine and Cangrelor. Thrombosis [DB61-GB90] [93]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Ticlopidine and Brilinta. Thrombosis [DB61-GB90] [48]
Argatroban DMFI46A Major Increased risk of bleeding by the combination of Ticlopidine and Argatroban. Thrombosis [DB61-GB90] [94]
Dicumarol DMFQCB1 Moderate Increased risk of bleeding by the combination of Ticlopidine and Dicumarol. Thrombosis [DB61-GB90] [52]
Clopidogrel DMOL54H Major Decreased metabolism of Ticlopidine caused by Clopidogrel mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [95]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Ticlopidine and Cabozantinib. Thyroid cancer [2D10] [96]
Tizanidine DMR2IQ4 Major Decreased metabolism of Ticlopidine caused by Tizanidine mediated inhibition of CYP450 enzyme. Tonus and reflex abnormality [MB47] [97]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Ticlopidine and Betrixaban. Venous thromboembolism [BD72] [93]
⏷ Show the Full List of 114 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Butylhydroxyanisole E00308 24667 Antimicrobial preservative; Antioxidant
Carmellose sodium E00625 Not Available Disintegrant
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Ticlopidine 250 mg tablet 250 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7307).
2 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 Effect of health foods on cytochrome P450-mediated drug metabolism. J Pharm Health Care Sci. 2017 May 10;3:14.
10 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
11 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
12 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
13 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
14 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
16 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
17 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
18 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
19 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
20 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
21 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
22 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
23 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
24 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
25 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
26 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
27 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
28 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
29 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
30 Cisplatin reduces Brucella melitensis-infected cell number by inducing apoptosis, oxidant and pro-inflammatory cytokine production. Res Vet Sci. 2010 Apr;88(2):218-26.
31 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
32 Thiols as peroxidase substrates. Free Radic Biol Med. 1993 Feb;14(2):167-75.
33 Proteomic profile of aminoglutethimide-induced apoptosis in HL-60 cells: role of myeloperoxidase and arylamine free radicals. Chem Biol Interact. 2015 Sep 5;239:129-38.
34 Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
35 Amino acid residues critical for endoplasmic reticulum export and trafficking of platelet-activating factor receptor. J Biol Chem. 2010 Feb 19;285(8):5931-40.
36 Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res. 2001 Sep;44(3):213-20.
37 Lexipafant and acute pancreatitis: a critical appraisal of the clinical trials.Eur J Surg.2002;168(4):215-9.
38 Effects of YM264, a novel PAF antagonist, on puromycin aminonucleoside-induced nephropathy in the rat. Biochem Biophys Res Commun. 1991 Apr 30;176(2):781-5.
39 The intestinal anti-inflammatory effect of dersalazine sodium is related to a down-regulation in IL-17 production in experimental models of rodent colitis. Br J Pharmacol. 2012 February; 165(3): 729-740.
40 Clinical pipeline report, company report or official report of 60 Degrees Pharmaceuticals.
41 Sch 37370: a new drug combining antagonism of platelet-activating factor (PAF) with antagonism of histamine. Agents Actions Suppl. 1991;34:313-21.
42 Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist. J Pharmacol Exp Ther. 1991 Oct;259(1):44-51.
43 Platelet-activating factor antagonist BN 50730 attenuates hypoxic-ischemic brain injury in neonatal rats. Pediatr Res. 2001 Jun;49(6):804-11.
44 Product Information. Ticlid (ticlopidine). Syntex Laboratories Inc, Palo Alto, CA.
45 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
46 Product Information. Ranexa (ranolazine). Calmoseptine Inc, Huntington Beach, CA.
47 Product Information. Onfi (clobazam). Lundbeck Inc, Deerfield, IL.
48 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
49 Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW "Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics." J Clin Pharmacol 42 (2002): 1219-27. [PMID: 12412820]
50 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
51 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
52 Gidal BE, Sorkness CA, McGill KA, Larson R, Levine RR "Evaluation of a potential enantioselective interaction between ticlopidine and warfarin in chronically anticoagulated patients." Ther Drug Monit 17 (1995): 33-8. [PMID: 7725374]
53 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
54 Product Information. Fragmin (dalteparin). Pharmacia and Upjohn, Kalamazoo, MI.
55 Cerner Multum, Inc. "Australian Product Information.".
56 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
57 Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4. [PMID: 8913401]
58 Product Information. Panhematin (hemin). Recordati Rare Diseases Inc, Lebanon, NJ.
59 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
60 FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide).".
61 Canadian Pharmacists Association.
62 Donahue S, Flockhart DA, Abernethy DR "Ticlopidine inhibits phenytoin clearance." Clin Pharmacol Ther 66 (1999): 563-8. [PMID: 10613611]
63 Ha-Duong NT, Dijols S, Macherey AC, Goldstein JA, Dansette PM, Mansuy D "Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19." Biochemistry 40 (2001): 12112-22. [PMID: 11580286]
64 Klotz U "The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications." Clin Pharmacokinet 46 (2007): 271-9. [PMID: 17375979]
65 Edeki TI, He HB, Wood AJJ "Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction." JAMA 274 (1995): 1611-3. [PMID: 7474246]
66 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
67 Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L "Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance." Br J Clin Pharmacol 48 (1999): 553-63. [PMID: 10583026]
68 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
69 Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
70 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
71 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
72 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
73 Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC.
74 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
75 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
76 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
77 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
78 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
79 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
80 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
81 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
82 Klinkhardt U, Kirchmaier CM, Westrup D, Graff J, Mahnel R, Breddin HK, Harder S "Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A." Clin Pharmacol Ther 67 (2000): 305-13. [PMID: 10741635]
83 Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
84 Caraco Y, Sheller J, Wood AJJ "Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects." J Pharmacol Exp Ther 290 (1999): 413-22. [PMID: 10381807]
85 Product Information. Noroxin (norfloxacin). Merck & Co, Inc, West Point, PA.
86 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
87 Carrillo JA, Ramos SI, Herraiz AG, Llerena A, Agundez JAG, Berecz R, Duran M, Benitez J "Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients." J Clin Psychopharmacol 19 (1999): 494-9. [PMID: 10587283]
88 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
89 Product Information. Saphris (asenapine). Schering-Plough Corporation, Kenilworth, NJ.
90 Krahenbuhl S, Sauter B, Kupferschmidt H, Krause M, Wyss PA, Meier PJ "Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication." Am J Med Sci 309 (1995): 315-6. [PMID: 7771501]
91 Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002): 391-401. [PMID: 12472978]
92 Product Information. Agrylin (anagrelide). Roberts Pharmaceutical Corporation, Eatontown, NJ.
93 Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3. [PMID: 27489634]
94 Product Information. Acova (argatroban) SmithKline Beecham, Philadelphia, PA.
95 Collet JP, Hulot JS, Pena A, et al. "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study." Lancet 373 (2009): 309-17. [PMID: 19108880]
96 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
97 Granfors MT, Backman JT, Laitila J, Neuvonen PJ "Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro." Br J Clin Pharmacol 57 (2004): 349-53. [PMID: 14998432]